학술논문

Delayed presentation of biopsy-proven eosinophilic myocarditis following COVID-19 mRNA vaccine.
Document Type
Article
Source
Global Cardiology Science & Practice. 2023, Vol. 2023 Issue 2, p1-12. 12p.
Subject
*COVID-19 vaccines
*MYOCARDITIS
*EOSINOPHILIA
*MEDICAL personnel
Language
ISSN
2305-7823
Abstract
Myopericarditis associated with COVID-19 mRNA vaccines has been recognized as an uncommon adverse reaction, especially among young, healthy adult males. Eosinophilic myocarditis is a rare form of inflammation reflecting a hypersensitivity reaction following an inciting event commonly caused by drugs including vaccines. Eosinophilic myocarditis, a subtype of myocarditis, is characterized by eosinophilic myocardial infiltrates. It is usually accompanied by systemic eosinophilia in the form of a drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and is rarely associated with myocyte fibrosis and/or necrosis. In this report, we present a case of biopsy-proven eosinophilic myocarditis in a 24-year-old male patient, likely secondary to COVID-19 mRNA vaccination. To our knowledge, this is the first report to describe delayed eosinophilic myocarditis following the COVID-19 mRNA vaccine. Clinicians should be aware of possible delayed presentation to avoid associated morbidity. [ABSTRACT FROM AUTHOR]